Drug Profile
Darinaparsin - Solasia Pharma
Alternative Names: Darvias; SP-02; SP-02L; Zinapar; ZIO-101Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator Texas A&M University; University of Texas M. D. Anderson Cancer Center
- Developer Nippon Kayaku; Solasia Pharma; ZIOPHARM Oncology
- Class Amines; Antineoplastics; Arsenicals; Oligopeptides; Pentanoic acids; Small molecules; Sulfides
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Peripheral T-cell lymphoma
- Discontinued Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 17 Jul 2023 Solasia Pharma announces intention to file for regulatory approval for Peripheral T-cell lymphoma in South America (Solasia Pharma pipeline, July 2023)
- 24 Aug 2022 Solasia plans a phase II/III trial in Peripheral T-cell lymphoma in European Union (Solasia Pharma pipeline, August 2022)
- 22 Aug 2022 First global launch - Launched for Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (IV)